Acadia confirms court ruling in favor of Nuplazid formulation patent

Acadia Pharmaceuticals (ACAD) announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for Nuplazid, the company’s drug for the treatment of Parkinson’s disease psychosis. The court ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other abbreviated new drug application filers, Acadia said in a statement “We are very pleased with today’s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038 This result highlights Acadia’s dedication to safeguarding our advancements in therapies for conditions with significant unmet medical needs,” said Catherine Owen Adams, Chief Executive Officer.